Search

The drug provides a new treatment option for people whose cancer has stopped responding to other therapies.

… Thursday, July 26, 2018 The US Food and Drug Administration has approved the drug ivosidenib (Tibsovo ® ) for the treatment of certain people with acute myeloid leukemia (AML) that has stopped responding to other therapies. Memorial Sloan Kettering hematologist-oncologist  Eytan Stein was a co-leader

The new findings suggest the need for caution when interpreting the results from these tests.

… Monday, November 25, 2019 Summary A comprehensive analysis led by researchers at Memorial Sloan Kettering has found that a large proportion of mutations found in liquid biopsies do not come from tumor cells, but rather from alterations in white blood cells. Blood tests called liquid biopsies have raised

Leukemia cells metabolize fructose in a way that could make them easier to target with drugs.

… Tuesday, December 22, 2020 Summary The way cancer cells process fructose has not been closely studied by researchers. A new study shows that some leukemia cells can break down fructose using a different metabolic pathway. This raises the possibility that giving fructose combined with drugs could be an

Learn the keys to a successful telemedicine visit from a cancer specialist at Memorial Sloan Kettering.

… Wednesday, May 27, 2020 Summary A Memorial Sloan Kettering cancer expert gives tips to patients on how they can be their own best advocates and feel confident, relaxed, and in control during telemedicine video visits with their cancer doctors. People with cancer and their doctors build a strong relationship

Aprenda las claves para una visita de telemedicina exitosa de parte de una especialista en cáncer en Memorial Sloan Kettering.

… Wednesday, May 27, 2020 Resumen Una experta en cáncer de Memorial Sloan Kettering da consejos a los pacientes sobre cómo pueden ser sus mejores defensores y sentirse seguros, relajados y en control durante las visitas de telemedicina por video con sus médicos especialistas en cáncer. Las personas con

Узнайте о том, что необходимо для успешного дистанционного приема, от онколога центра Memorial Sloan Kettering.

… Wednesday, May 27, 2020 Краткое изложение Специалист по онкологии из центра Memorial Sloan Kettering дает советы пациентам по поводу того, как наилучшим образом представлять свои интересы, чувствовать себя уверенно и спокойно и сохранять контроль над ситуацией во время дистанционного видеоприема у врача-онколога

A new discovery made by Memorial Sloan Kettering researchers and published in the journal Nature Genetics, identifies a mechanism for the triggering of solid tumors — including most types of cancers that affect children and young adults. For more information or to arrange interviews, e-mail Rebecca Williams at [email protected].

… Monday, May 15, 2017 Bottom Line :  A new discovery published in the journal Nature Genetics identifies a mechanism for the triggering of solid tumors — including most types of cancers that affect children and young adults. The enzyme made by the gene PGBD5 cuts DNA segments and then rearranges them.

Cancer progression is commonly thought of as a process involving the growth of a primary tumor followed by metastasis, in which cancer cells leave the primary tumor and spread to distant organs. A new study by researchers at Memorial Sloan Kettering Cancer Center shows that circulating tumor cells - cancer cells that break away from a primary tumor and disseminate to other areas of the body - can also return to and grow in their tumor of origin, a newly discovered process called "self-seeding."

… Thursday, December 24, 2009 Cancer progression is commonly thought of as a process involving the growth of a primary tumor followed by metastasis, in which cancer cells leave the primary tumor and spread to distant organs. A new study by researchers at Memorial Sloan Kettering Cancer Center shows that

… Friday, November 8, 2024 Memorial Sloan Kettering Cancer Center (MSK) issued the following statement regarding its financial results for the first three quarters of 2024:   MSK’s financial performance through the third quarter of 2024 demonstrate positive and consistent financial results, with an excess

New data from researchers at MSK featured in the 2022 ASCO Annual Meeting press program and simultaneously published in The New England Journal of Medicine highlights a novel antibody-drug conjugate that doubled progression-free survival in HER2-low metastatic breast cancer.

… Sunday, June 5, 2022 Update: On August 5, 2022, the FDA approved the first targeted therapy for patients with HER2-low  breast cancer  that has spread to other parts of the body and is unable to be surgically removed. The drug,  https://www.mskcc.org/cancer-care/patient-education/fam-trastuzumab-deruxtecan